TNFRSF10B and soft tissue neoplasm: Inclusion criteria were studies from 2017 to 2024; any in vitro, in vivo, or clinical studies in the English language investigating DR5 as a target for imaging or as an agonist to induce apoptosis in primary bone and soft tissue tumors; and published and unpublished work (gray literature), supplements, proceedings of meetings, or conference abstracts.